In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma-Reference-Cited by-同舟云学术

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

Published:2009-11-30 Issue:5 Volume:95 Page:794-803
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Ocio E. M.,Vilanova D.,Atadja P.,Maiso P.,Crusoe E.,Fernandez-Lazaro D.,Garayoa M.,San-Segundo L.,Hernandez-Iglesias T.,de Alava E.,Shao W.,Yao Y. M.,Pandiella A.,San-Miguel J. F.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships;European Journal of Medicinal Chemistry;2024-07

2. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

3. Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice;Life Sciences;2023-12

4. Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?;Pathology - Research and Practice;2023-08

5. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses;Biomedicine & Pharmacotherapy;2023-08